{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:55:24Z","timestamp":1792194924241,"version":"4.4.0"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371840"],"award-info":[{"award-number":["82371840"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472912"],"award-info":[{"award-number":["82472912"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471866"],"award-info":[{"award-number":["82471866"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271877"],"award-info":[{"award-number":["82271877"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["RDX2024\\u201301"],"award-info":[{"award-number":["RDX2024\\u201301"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["RDGS2022\\u201302"],"award-info":[{"award-number":["RDGS2022\\u201302"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park","doi-asserted-by":"publisher","award":["Z221100007422097"],"award-info":[{"award-number":["Z221100007422097"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2507000"],"award-info":[{"award-number":["2023YFC2507000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024ZD0525700"],"award-info":[{"award-number":["2024ZD0525700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7242150"],"award-info":[{"award-number":["7242150"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017003","name":"Peking University Health Science Center","doi-asserted-by":"publisher","award":["BMU2024BSS001"],"award-info":[{"award-number":["BMU2024BSS001"]}],"id":[{"id":"10.13039\/501100017003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.phrs.2025.107968","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T08:10:03Z","timestamp":1758701403000},"page":"107968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["FGFR3 alteration sites and response rate to FGFR inhibitors in urothelial carcinoma"],"prefix":"10.1016","volume":"221","author":[{"given":"Yuxuan","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caipeng","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2025.107968_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107805","article-title":"Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): a 2025 update","volume":"217","author":"Roskoski","year":"2025","journal-title":"Pharm. Res."},{"issue":"9","key":"10.1016\/j.phrs.2025.107968_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006643","article-title":"Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment","volume":"11","author":"Song","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.phrs.2025.107968_bib3","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.eururo.2020.07.018","article-title":"Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial carcinoma","volume":"78","author":"Teo","year":"2020","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.phrs.2025.107968_bib4","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.107968_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107543","article-title":"Efficacy and safety of selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors in FGFR-altered urothelial carcinoma","volume":"211","author":"Song","year":"2025","journal-title":"Pharm. Res."},{"issue":"8","key":"10.1016\/j.phrs.2025.107968_bib6","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.phrs.2025.107968_bib7","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1158\/2159-8290.CD-22-1441","article-title":"Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer","volume":"13","author":"Facchinetti","year":"2023","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.phrs.2025.107968_bib8","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jamaoncol.2024.3900","article-title":"Rogaratinib plus atezolizumab in Cisplatin-Ineligible patients with FGFR RNA-Overexpressing urothelial cancer: the FORT-2 phase 1b nonrandomized clinical trial","volume":"10","author":"Sweis","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.phrs.2025.107968_bib9","doi-asserted-by":"crossref","first-page":"107230","DOI":"10.1016\/j.phrs.2024.107230","article-title":"Effect of FGFR alteration on prognosis in 1963 urothelial carcinoma patients with immune checkpoint inhibitors: Implying combination of FGFR inhibitor and immunotherapy for FGFR-altered urothelial carcinoma","volume":"205","author":"Song","year":"2024","journal-title":"Pharm. Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825003937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825003937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:45:34Z","timestamp":1773153934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825003937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":9,"alternative-id":["S1043661825003937"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107968","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGFR3 alteration sites and response rate to FGFR inhibitors in urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107968","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107968"}}